Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefazolin sodium, quantity: 524 mg - injection, powder for - excipient ingredients: - cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms:,respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci.,injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.,cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present.,genitourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species, and some strains of enterobacter and enterococci.,skin and skin structure infections due to staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci and other strains of streptococci.,bone and joint infections due to staph. aureus.,septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin-resistant), pr. mirabilis, esch. coli and klebsiella species.,endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - caspofungin acetate, quantity: 55.5 mg (equivalent: caspofungin, qty 50 mg) - injection, powder for - excipient ingredients: sodium hydroxide; sucrose; hydrochloric acid; mannitol - caspofungin amneal is indicated for:,? empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics,? treatment of:,-invasive candidiasis, including candidaemia,-oesophageal candidiasis,-invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - caspofungin acetate, quantity: 77.7 mg (equivalent: caspofungin, qty 70 mg) - injection, powder for - excipient ingredients: sodium hydroxide; sucrose; hydrochloric acid; mannitol - caspofungin amneal is indicated for:,? empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics,? treatment of:,-invasive candidiasis, including candidaemia,-oesophageal candidiasis,-invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - linezolid -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - atomoxetine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - atomoxetine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - atomoxetine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - atomoxetine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - atomoxetine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - atomoxetine hydrochloride -